<DOC>
	<DOCNO>NCT00057005</DOCNO>
	<brief_summary>Participants study hematologic malignancy disorder bone marrow affect body 's ability create blood . Participants might benefit receive allogeneic stem cell transplant ( mean cell come donor ) . The participant donor family member . Stem cell cell bone marrow blood form whole new blood system .</brief_summary>
	<brief_title>Anti-Human CD45 Monoclonal Antibodies Patients With Advanced Leukemia Prior Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Patients give high dos chemotherapy receive stem cell transplant keep immune system reject donor stem cell kill diseased cell remain body . To try improve result transplant use high dose chemotherapy alone , add agent call anti-CD45 treatment prior stem cell transplant . Anti-CD45 antibody specifically find destroys leukemia cell . Patients receive anti-CD45 high dose chemotherapy ( include Ara-C Cyclophosphamide ) radiotherapy . Patients also receive Mesna drug help prevent bladder damage cause cyclophosphamide . High dose radiotherapy also know Total Body Irradiation TBI . Patients receive anti-CD45 , high dose chemotherapy , high dose radiotherapy stem cell transplant . We expect participation study last 2 year . A summary treatment follow : - Day - 7 : Ara-C , Cyclophosphamide , Mesna - Day - 6 : Ara-C , Cyclophosphamide , Mesna - Day - 5 : Ara-C , Anti-CD45 - Day - 4 : Anti-CD45 , TBI - Day - 3 : Anti-CD45 , TBI - Day - 2 : Anti-CD45 , TBI - Day - 1 : TBI - Day 0 : Stem Cell Infusion ( transplant )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients advance leukemia hematologic malignancy include AML , ALL , CML , MDS . Advanced feature include : ) Induction failure , prolonged induction beyond 6 week b ) Incomplete response salvage therapy c ) CML blast crisis acute leukemia chemotherapy resistant relapse ) secondary leukemia secondary myelodysplastic disease 2 . Patients must suitable HLA identical sibling donor 5/6 match related donor , fully match 5/6 match unrelated donor , haploidentical relate donor . 1 . Patients life expectancy ( 2X normal age ) 7 . Patients know allergy rat serum product 8 . Patients Lansky score &lt; 60 % Karnofsky score &lt; 60 % . 9 . Patients severe infection evaluation PI preclude ablative radio/chemotherapy successful transplantation . 10 . Patients sever personality disorder mental illness . 11 . Patients document HIV positivity 12 . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>LEUKEMIA</keyword>
</DOC>